The Food and Drug Administration has approved osimertinib, also referred to as Tagrisso, an innovative targeted therapy medication, for the therapy of non-small cell lung carcinoma (NSCLC).This drug, which precisely addresses the EGFR (epidermal growth factor receptor) mutation, a common genetic mutation in NSCLC patients, has been designed.We will delve into the significance of osimertinib as a target in cancer therapy, exploring its mode of action, advantages, and possible drawbacks in this article.Through inhibiting the activity of the EGFR, which is responsible for facilitating the growth and proliferation of cancer…
